KLRA vs KPRX

Kailera Therapeutics, Inc. vs Kiora Pharmaceuticals, Inc. — Valuation Comparison 2026

KLRA

Biotechnology
Kailera Therapeutics, Inc.
Quality
1.7
out of 10
Value Trap
Price
$22.94
Last close
Models
5/13
Active
VS

KPRX

Biotechnology
Kiora Pharmaceuticals, Inc.
Quality
5.5
out of 10
Value Trap
33
LOW
Price
$2.83
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType KLRA Fair ValueKLRA Upside KPRX Fair ValueKPRX Upside
Bayesian DCF Intrinsic $6.77 -70.5% $2.06 -27.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.48 -84.8% $0.48 -80.2%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for KLRA vs KPRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KLRA vs KPRX — Which Stock Is More Undervalued?

KPRX scores higher with a 5.5/10 quality rating vs KLRA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kailera Therapeutics, Inc. (KLRA) and Kiora Pharmaceuticals, Inc. (KPRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KLRA currently trades at $22.94 with a QOC of 1.7/10, while KPRX trades at $2.83 with a QOC of 5.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).